UK markets open in 3 hours 45 minutes
NIKKEI 225
38,303.39 -531.71 (-1.37%) HANG SENG
18,559.27 +79.90 (+0.43%) CRUDE OIL
78.04 -0.34 (-0.43%) GOLD FUTURES
2,324.30 +0.10 (+0.00%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,241.07 -728.33 (-1.43%)
Clinuvel Pharmaceuticals Limited (CUV.XA)
Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
As of 01:14PM AEST. Market open.
| Previous close | 15.31 |
| Open | 15.45 |
| Bid | 15.40 x N/A |
| Ask | 15.43 x N/A |
| Day's range | 15.28 - 15.56 |
| 52-week range | 12.98 - 21.43 |
| Volume | |
| Avg. volume | 20,293 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 32.80 |
| EPS (TTM) | 0.47 |
| Earnings date | 22 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Is Clinuvel Pharmaceuticals Limited's (ASX:CUV) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Clinuvel Pharmaceuticals' (ASX:CUV) stock is up by a considerable 8.7% over the past month. Since the market usually...
GlobeNewswirePhotomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years
- Simply Wall St.
Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years ago
Investing in stocks inevitably means buying into some companies that perform poorly. Long term Clinuvel Pharmaceuticals...
© 2024 Yahoo. All rights reserved.